We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+4.31%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.43B
AUM Growth
+$292M
Cap. Flow
+$65.8M
Cap. Flow %
4.59%
Top 10 Hldgs %
64.89%
Holding
82
New
14
Increased
33
Reduced
12
Closed
20

Top Buys

Rank Stock Value
1
CYH icon
Community Health Systems
CYH
+$37.3M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$35M
3
AMRN
Amarin Corp
AMRN
+$19.9M
4
AMED
Amedisys
AMED
+$19.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.7M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$77.7M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$27.1M
3
NVST icon
Envista
NVST
+$21.6M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$17.9M
5
HLN icon
Haleon
HLN
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 76.06%
2 Miscellaneous 22.43%
3 Financials 0.95%
4 Communication Services 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$168M 11.7%
+410,000
New +$164M
NTRA icon
2
Natera
NTRA
$47B
$157M 10.92%
2,819,770
+133,811
+5% +$6.42M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$489B
$144M 10.07%
+450,000
New +$133M
GSK icon
4
GSK
GSK
$102B
$134M 9.34%
3,731,499
+241,042
+7% +$8.43M
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$89.4M 6.23%
819,124
-245,322
-23% -$27.1M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$42.5B
$54.8M 3.82%
6,194,572
+1,481,975
+31% +$14.7M
UTHR icon
7
United Therapeutics
UTHR
$22.1B
$49.7M 3.47%
222,107
-10,680
-5% -$2.63M
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.74B
$46.7M 3.25%
2,209,057
+588,344
+36% +$14.6M
CYH icon
9
Community Health Systems
CYH
$413M
$44.5M 3.1%
9,082,305
+7,080,311
+354% +$37.3M
BIIB icon
10
Biogen
BIIB
$32.3B
$42.8M 2.98%
153,774
+16,426
+12% +$4.55M
ILMN icon
11
Illumina
ILMN
$32.6B
$39.7M 2.77%
175,312
+31,323
+22% +$6.41M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.51B
$37.7M 2.63%
4,520,724
+3,640,237
+413% +$35M
CTLT
13
DELISTED
CATALENT, INC.
CTLT
$37.7M 2.63%
573,609
-118,068
-17% -$7.3M
DHR icon
14
Danaher
DHR
$152B
$37.5M 2.62%
167,717
-15,663
-9% -$3.56M
CLDX icon
15
Celldex Therapeutics
CLDX
$3.07B
$24.8M 1.73%
689,676
+130,902
+23% +$5.65M
AMRN
16
Amarin Corp
AMRN
$295M
$21.9M 1.53%
730,638
+566,432
+345% +$19.9M
CNC icon
17
Centene
CNC
$32B
$18.2M 1.27%
288,426
+73,865
+34% +$5.24M
AMED
18
DELISTED
Amedisys
AMED
$16.5M 1.15%
+224,263
New +$19.4M
ICLR icon
19
Icon
ICLR
$13.1B
$16.4M 1.14%
76,788
+10,095
+15% +$2.25M
AVTR icon
20
Avantor
AVTR
$9.86B
$15.2M 1.06%
717,614
+117,414
+20% +$2.68M
MCRB icon
21
Seres Therapeutics
MCRB
$51.3M
$14.4M 1%
126,833
+16,783
+15% +$1.82M
TECH icon
22
Bio-Techne
TECH
$11.3B
$14M 0.98%
188,659
+172,024
+1,034% +$13.3M
VERA icon
23
Vera Therapeutics
VERA
$2.46B
$13.9M 0.97%
1,788,529
+1,377,221
+335% +$10.6M
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$11.8M 0.83%
+218,726
New +$10.6M
EHTH icon
25
eHealth
EHTH
$38.4M
$11.6M 0.81%
+1,234,283
New +$9.7M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Eversept Partners held 82 positions worth $1.43B, up 26% from $1.14B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Eversept Partners deployed $65.8M of net new capital in Q1 2023, opening 14 new positions and adding to 33 existing holdings. Its largest new stake was Amedisys: 224,263 shares worth $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $27.1M trimmed.

  • Eversept Partners's largest Q1 2023 buy was Amedisys: 224,263 shares worth $16.5M.
  • Eversept Partners added most to Community Health Systems in Q1 2023, an estimated $37.3M increase.
  • Eversept Partners's biggest Q1 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $27.1M.
  • Eversept Partners fully exited Sanofi in Q1 2023, selling an estimated $77.7M.
  • Eversept Partners's ten largest holdings make up 65% of its $1.43B portfolio in Q1 2023.
  • Eversept Partners opened 14 new positions and closed 20 in Q1 2023.
  • Eversept Partners's portfolio value rose 26% quarter-over-quarter to $1.43B.

Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.